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Abstract
Background: A significant proportion of trial participants respond to placebos for a variety of
conditions. Despite the common conduct of these trials and the strong emphasis placed on
informed consent, very little is known about informing participants about their individual treatment
allocation at trial closure. This study aims to address this gap in the literature by exploring
treatment beliefs and reactions to feedback about treatment allocation in the participants of a
placebo-controlled randomized clinical trial (RCT).
Methods: Survey of trial participants using a semi-structured questionnaire including close and
open-ended questions administered as telephone interviews and postal questionnaires. Trial
participants were enrolled in a double-blind placebo-controlled RCT evaluating the effectiveness of
corticosteroid for heel pain (ISRCTN36539116). The trial had closed and participants remained
blind to treatment allocation. We assessed treatment expectations, the percentage of participants
who wanted to be informed about their treatment allocation, their ability to guess and reactions
to debriefing.
Results: Forty-six (73%) contactable participants responded to our survey. Forty-two were
eligible (four participants with bilateral disease were excluded as they had received both
treatments). Most (79%) participants did not have any expectations prior to receiving treatment,
but many 'hoped' that something would help. Reasons for not having high expectations included the
experimental nature of their care and possibility that they may get a placebo. Participants were
hopeful because their pain was so severe and because they trusted the staff and services. Most
(83%) wanted to be informed about their treatment allocation and study results. Over half (55%)
said they could not guess which treatment they had been randomized to, and many of those who
attempted a guess were incorrect. Reactions to treatment debriefing were generally positive,
including in placebo responders.
Conclusion: Our study suggests that most trial participants want to be informed about their
treatment allocation and trial results. Further research is required to develop measure of hope and
expectancy and to rigorously evaluate the effects of debriefing prospectively.
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Background
One of the most famous examples of the placebo effect is
an account given by Dr. Klopfer of a trial patient with
advanced cancer randomized to a new drug called 'Kebri-
ozen'. Klopfer describes how within ten days: 'all signs of
his disease [had] vanished'. The patient relapsed within
two months when he learned that trials results were
inconclusive. His clinician somehow managed to con-
vince the patient that he had: 'a new super refined, double
strength product', but instead administered saline injec-
tions. The patients' response to these injections was
described as: 'even more dramatic than the first'. He
remained symptom free for over two months, until he
read that: "nationwide tests show Krebiozen to be a
worthless drug in treatment of cancer". Within a few days
of this report, Mr. Wright was readmitted to the hospital
in extremis. His faith was now gone, his last hope van-
ished, and he succumbed in less than two days' [1].
Much has been written on the ethics of obtaining
informed consent from trial participants [2] and the ethics
of using placebos in clinical trials [3,4]. However, the eth-
ics of debriefing ('disclosing', 'unmasking', 'unblinding'),
at study closure has been overlooked. Debriefing consists
of informing trial participants about their individual treat-
ment allocation and study results. Research in this area is
scarce, but it is of particular relevance for placebo-control-
led trial participants.
There is some evidence that these participants may be kept
in the dark about their allocation once the experiment is
over. In a survey published in the British Medical Journal,
we found that less than half of trial investigators informed
participants of placebo-controlled trials about their treat-
ment allocation at trial closure [5]. The most common
reason for continuing to keep patients 'blind' was that
investigators had: 'never considered the option of inform-
ing patients'. This is despite government standards for
research emphasizing the need to debrief and share study
findings with participants [6].
Debriefing shows respect and appreciation to trial partici-
pants and it symbolises investigators' desire to involve
patients and share the knowledge gathered during the
experiment. However, debriefing placebo responders can
also be disruptive. Unless information is disclosed sensi-
tively and effectively (e.g. in the context of trial results and
explaining what is understood to trigger a placebo effect),
healing reactions in placebo responders may be broken.
In one trial[7], when placebo responders were told that
the treatment allocated to them had been a placebo, most
of them relapsed and had to be prescribed the 'real' med-
ication[8]. In a separate trial, though fetal-cell implanta-
tion was found to be as effective as sham surgery for
Parkinson patients, most of the placebo responders still
wanted to receive the implants once treatment allocation
was unblinded a year later[9]. When patients who had
received the sham surgery were told that they could not
receive the real but now 'discredited' surgery they had
been promised during the informed consent stage, 70%
were disappointed and 'outraged' because of the dramatic
effects they had already received from the sham sur-
gery[10]. These findings suggest that just like patients who
think they have received an active treatment can have sig-
nificant physiological and psychological improve-
ments[11], patients who learn they have actually been
deceived with a sham treatment can worsen.
Our knowledge around treatment debriefing in the partic-
ipants of placebo-controlled trials is scarce and based on
a handful of reports. In this study we set out to fill this gap
in the literature by: 1) exploring treatment expectations;
2) ability to guess treatment allocation; 3) wish to be
debriefed and 4) reactions to unmasking in the partici-
pants of a placebo-controlled RCT testing the effectiveness
of corticosteroid for heel pain.
Plantar heel pain is a common painful condition where
placebo effects have been shown to exist[12]. A systematic
review of interventions for the management of the painful
heel was unable to find compelling evidence of effective-
ness for any of the therapies evaluated in RCTs. While var-
ious interventions are used to treat it, including steroid
injections, there is limited evidence for their effective-
ness[13,14]. In an RCT evaluating the effectiveness of a
corticosteroid injection in the treatment of plantar heel
pain, one of us found that corticosteroid was effective at
one month, but not at three and six months[15], and par-
ticipants were not informed about their treatment alloca-
tion at study closure. The trial was conducted between
January 1995 and December 1998 at the Center for Rheu-
matology, University College London.
The control used in this trial was a local anaesthetic. This
is an active drug, but because is is assumed to be ineffec-
tive for plantar heel pain, it was used as a credible placebo
in this trial. Anaesthetic effects are short-term (5–6
hours), and the earliest evaluation of a therapeutic effect
following treatment in this trial was at 1 month. Its effects
are therefore thought to be 'non-specific'. Not least of all
because at the time the outcomes were collected local
anaesthetic would be pharmacologically inert (i.e. the
effect of numbness would have worn off).
Methods
Patient and GP contact details were obtained from the
hospital database of the original trial. The boxes (Fig. 1)
illustrate the patient recruitment process.
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Ethics approval was received from University College Lon-
don ethics committee. Following guidance and ethical
approval we wrote one letter and used two follow-up
reminders to seek the consent of the trial patients' GPs for
us to re-establish contact with them. For GPs who gave
permission, a letter was written to each patient inviting
them to share their experiences of the treatment received
and satisfaction with the care provided for their heel pain.
Telephone contact was made by the first author (ZDB)
and data gathered from January 2000 to April 2000, using
a semi-structured questionnaire developed in collabora-
tion with two chartered health psychologists.
Participants were asked general questions about their heel
pain (e.g. beliefs about possible causes), and open ques-
tions about what they remember of the study and the doc-
tor who treated them. We asked closed questions to assess:
(i) Treatment expectations ("Before you were given the injec-
tion, did you have any expectations about how effective it would
be?", "Were your expectations: 'very high', 'somewhat high',
'not sure', or 'low"'?);
(ii) Ability to guess treatment allocation ("What treatment
do you think you got?', 'How confident are you that you got X"?
with responses ranging from: 'very confident' to 'not at all
confident');
(iii) Wish to be debriefed ("Would you like to know what you
got?", "Would you like to know the overall study results?").
Flowchart of recruitment processigure 1
Flowchart of recruitment process
Patients in the
original trial (n=91) Contact addresses
not available (n=15)
GPs contacted for
permission to contact
patients (n=76)
Contact addresses
not available (n=13)
Patients contactable
(n=63)
32 interviewed by
phone
No of patients
surveyed (n=46)
4 patients had
bilateral disease
Original Trial 1995-1998
Ethics Approval Obtained
Sept 1999
GP contact Patients in the
Nov-Dec 1999
Patient contact
Jan-April 2000
Excluded
5 Refused 12 patients
never replied
37 were contactable
contactable by
phone
14 patients replied to
postal questionnaire
26 were contactable
by mail
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Recordings of reaction to debriefing about treatment allo-
cation and study results were left open. Responses were
not tape recorded, but typed in shorthand and transcribed
directly on a computer file. Patients who could not be
contacted by phone were mailed a letter and a postal ques-
tionnaire, asking them to include a telephone number if
they wanted to be contacted about their treatment
allocation.
Analysis
Narrative descriptions were integrated with the quantita-
tive data derived from the original trial. Patients who had
a lower pain score from baseline to one month and who
had been allocated to the local anaesthetic were described
as 'placebo responders' (PR). Those who did not respond
at one month were described as 'placebo non responders'
(PNR). Participants who had a lower pain score one
month after treatment and who had been allocated to the
steroid arm were described as 'steroid responders' (SR),
while those who didn't respond to the steroid at one
month were described as 'non responders' (SNR). The
main outcome was pain was assessed using a 10 cm Visual
Analogue Scale (VAS), where '0' indicated no pain and
'10' indicated worst pain imaginable.
Results
Contact details of 76 of the original 91 GPs and patients
were available. GPs notified us not to contact 13 of the 76
patients (1 deceased, 1 terminally ill, 1 under investiga-
tion, 6 had moved away, no records for 2, no reason given
for 2). A total of 63 patients were invited to take part in
our study. All patients for whom we had a telephone
number were telephoned. Of these, 32 patients agreed to
be interviewed and five refused (2 were sick and 1 was car-
ing for a sick person; 2 did not give a reason). Twenty-six
participants were not contactable by telephone as their
number was not obtainable (6), it was ex-directory (2),
wrong (6), or always engaged (5), four had no phone and
three had moved away. In order to increase our response
rate, postal questionnaires were mailed to the 26 patients
who were not contactable by telephone. Fourteen of the
26 (54%) patients responded to our postal questionnaire.
A total of 73% contactable individuals (46 of 63) agreed
to participate in our survey.
In the original trial, treatments were randomized to epi-
sodes of heel pain, rather than per patient. There were 91
patients with 106 episodes of heel pain. Seven of these
patients had bi-lateral heel pain and it was possible for
these patients to receive both steroid and placebo injec-
tion, or 2 steroid injections, or 2 placebo injections. These
individuals were excluded from this survey.
A total of 53 episodes of pain were randomized to placebo
and 53 were randomized to steroid. Corticosteroid was
found to be significantly more effective than the local
anaesthetic at one month, but not at three or at six
months. Twenty-eight percent of the entire trial popula-
tion still had heel pain at the end of the trial.
In the present follow-up we contacted 46 patients with 49
episodes of pain (51% of the original trial). Of these, four
patients were excluded because they had bilateral disease.
Our total sample consisted of 42 participants. Of these, 24
patients had been randomized to receive a steroid injec-
tion and 18 had been randomly allocated to receive a
local anaesthetic, or placebo. Eighteen of 24 (75%)
patients who were randomized to the steroid injection
responded (SR), and 7 of 18 (39%) of patients who were
randomized to the placebo responded (PR). Six partici-
pants who received a steroid injection failed to respond
(SNR) and 11 participants who received a local anaes-
thetic did not respond (PNR). A detailed description and
analysis of pain scores is provided in a previous publica-
tion from the original trial[16].
1. Participants' expectations about treatment
Trial participants were asked whether they had any expec-
tations about the effectiveness of the treatment, prior to
receiving this. Most (79%) said they did not have any
expectations prior to receiving treatment, but 'hoped'
something would help. For this reason we asked partici-
pants how hopeful they were that the treatment would
help them (see Table 1).
A total of 38% (16 of 42) said they weren't sure about how
effective the treatment would be prior to receiving this.
Four participants explained that they didn't know what to
expect because of the artificial nature of their care ("As far
Table 1: Treatment Expectations in trial participants
PR n (%) PNR n (%) SR n (%) SNR n (%) TOTAL n (%)
Very Hopeful - 3 (27%) 7 (39%) 1 (17%) 11 (26%)
Hopeful 3 (43%) 4 (36%) 2 (11%) 2 (33%) 11 (26%)
Not sure 4 (36%) 4 (36%) 6 (33%) 2 (33%) 16 (38%)
Not hopeful - - 3 (17%) 1 (17%) 4 (9%)
PR: Placebo Responder; PNR: Placebo Non Responder; SR: Steroid Responder: SNR: Steroid Non Responder
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as I remember the treatment was coded so that they could not
be immediately identifiable", "No idea, I wasn't told", "I knew
it was an experiment and there was no way of knowing that it
would help", "50/50 because there was no guarantee that it
would cure it").
About half of the participants (52%, 22 of 42) said they
were either 'very hopeful' or 'hopeful' (e.g. "I didn't have
any expectations, I hoped something would help"). Reasons for
being hopeful included the fact that the pain was so severe
("Very hopeful because of the pain, it was extraordinary that it
just came and stayed like that", "You really hope because the
pain is so bad, and it can be quite disappointing", "Hopeful, I
really wanted to continue with my life without the pain I was
experiencing"), the credibility of the staff ("Very hopeful ...
they seemed to be very efficient; they seemed to know what they
were doing"), and trust in the health services ("I thought it
would cure it, I felt definite. I have a feeling that if I go to hos-
pital they are going to do their utmost and will do their best so
I am quite happy and relaxed about that"). Another partici-
pant said she was open to give the treatment a try (e.g. "I
felt I would give it a try as I had already tried acupuncture and
massage and they didn't help. I knew it was a treatment and
that it was part of a trial, but I was happy to give it a go").
Nine percent (4 of 42) said they were not hopeful, three
of which were steroid responders. Reasons for not being
hopeful included previous experience with healthcare
("Not very hopeful. Normally when you go to hospital you have
to return a few times").
Three participants commented on the fact that they did
not expect the injection to be so painful ("didn't really have
any expectations ... I didn't know how painful it would be but
it was terrible. I have had worse, but it was bad', "The injection
was more painful than I had expected and I am used to injec-
tions", "Having the injection was quite painful, more than I
expected").
2. Guessing treatment allocation
When asked what treatment they thought they got, just
over half (22 of 42, 55%) said they didn't know. Only 7
of the 19 (37%) participants who attempted a guess were
correct about their treatment allocation, four were steroid
responders (Table 2).
The local anaesthetic or placebo was described as: "a
dummy", "the wrong one", "the one with nothing in it", "plain
water", and "the one that wasn't going to work", while the
active treatment was described more positively as: "a new
treatment", "a new formula", "the right one", the "pain killer",
and the "real one".
One of the participants said he tried to guess what treat-
ment the therapist was administering by looking into his
eyes but he was still unable to break the blind ("I did look
into his eyes carefully to see what it was he was giving me. He
looked interested and pleased to see I wasn't in pain, but I sup-
pose that is because he is a doctor, he is happy when patients get
better").
A placebo responder explained that he did not know what
he got because he felt that both treatments could be effec-
tive ("Whether it was faith or a chemical interaction, I don't
know, but it was effective. You can't be sure of anything, you
have to leave the possibilities") and a steroid responder said
he trusted in natural self-healing responses ("I think some
things go away by themselves, you just give the injection and it
doesn't matter what's in it. I know these things. I am a GP. My
hunch is that it was only a local"). When asked what treat-
ment he got, a steroid participant confidently guessed that
this was a placebo, attributing his improvement to relaxa-
tion ("An anaesthetic, I'm confident. I think that after the pain
I was more relaxed and the pain wasn't as bad. When I am
nervous and I am thinking about the pain it's worse and it
comes back").
3. Wish to be debriefed
Most (83%, 35 of 42) trial participants wanted to know
what treatment had been allocated to them (see Table 3).
One participant was upset that he had never been
debriefed: "They should have written to everyone ... they are
obliged to inform patients. Patients are treated almost as chil-
Table 2: Beliefs about Treatment
PR n (%) PNR n (%) SR n (%) SNR n (%) TOTAL n (%)
It was a 'placebo' or 
an anaesthetic
------ 2 (18%) 3 (17%) X 1 (17%) X 6 (14%)
It was a steroid or the 
'real' thing
2 (29%) X 6 (54%) X 4 (22%) 1 (17%) 13 (31%)
I don't know 5 (71%) 3 (27%) 11 (61%) 4 (67%) 23 (55%)
PR: Placebo Responder; PNR: Placebo Non Responder; SR: Steroid Responder: SNR: Steroid Non Responder; Correct answer:  Incorrect 
answer:X
9
9 9
9
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dren ... they [investigators] just want to know about their
experiments".
Five participants preferred not to be debriefed (e.g. "I am
fine now"). One participant was very upset because of neg-
ative experiences following the injection and another
insisted that he had not participated in the study ("They
just went with the corticosteroid with me, I never had the option
of the other on"). These two participants were not
debriefed.
All participants who wanted to be debriefed about their
treatment allocation, also wanted to be informed about
study results. Participants were told that: "Corticosteroid
was found to be significantly more effective than local anaes-
thetic at one month, but not at three and at six months".
4. Reactions to treatment debriefing
Reactions to debriefing in placebo responders ranged
between slight embarrassment ("Really? That makes me feel
really silly, oh my God! ... I am cringing now") to amazement
and excitement ("That is fantastic. That is a discovery!
Human chemistry is the most effective of them all. I am really
thrilled to hear I was given a local anaesthetic ... It is the faith,
the trust we put in people").
There was a similar variation among active treatment
responders, between those who were thrilled to hear they
got better thanks to a 'real' drug ("It was? They couldn't fool
me!"), to those who believed that healing results sponta-
neously and incorrectly guessed that they had received a
placebo, and were surprised to hear they had been
injected with corticosteroid ("It was? Oh, there you go...").
Two placebo non-responders incorrectly guessed the treat-
ment allocated to them had been the active treatment.
When they were debriefed, both as well as a placebo non
responder attributed their improvement to physiotherapy
("The physiotherapy helped a lot", "The physiotherapy was
lovely, I could have managed without the injection, so I can't
really say which was more effective", "Oh right, I did have it
(heel pain) after the injection, but they it started going after the
physiotherapy, I suddenly woke up one morning, and I was able
to put it (the foot) down").
Many of the reactions to study results tended to be excla-
mations ("Mmmmm", "Right", "Ahhh", "Ohh", "Fair
enough", "Interesting"). Three participants were very
pleased to hear the study results ("I am delighted to find out
about the treatment and results. I am very satisfied with the
study", "These are really interesting findings", "I think these
(results) are right!").
Three asked to find out more information about the study
("Interesting, I would really like to read more about it", "I
would really like to read the study, would you mind sending me
a copy? So you are doing a study of the study, that's interest-
ing", "I am always interested in research, please send me a copy
of the paper").
One participant asked what have we learned from this
study and where do we go from here. She suggested that
there should be more information for heel pain patients
about the causes of heel pain and guidelines to help prac-
tice self-care.
Discussion
In our study, most (79%, 33 of 42) trial participants said
they did not have any 'expectations' prior to receiving
treatment, but rather 'hoped' that something would help.
This finding was surprising, considering that treatment
expectations are considered to be one of the principle
mechanisms of placebo effects [17-19].
We were not able to find a satisfying definition of 'hope'
as distinct from 'expectation'. Both tend to be described as
beliefs that a desired outcome will occur, with hopes often
having an element of expectation[19]. Common use of
the concepts would suggest that hopes are accompanied
with a lesser degree of certainty than expectation, perhaps
allowing for the possibility of dealing with disappoint-
ment. One of the participants in our survey explained how
"You really hope because the pain is so bad, and it can be quite
disappointing".
Our findings are supported by those of a recent qualitative
and in depth study examining expectations in the partici-
pants of a placebo-controlled RCT [20]. The team found
that only one of the nine participants expected to experi-
Table 3: Wish to be debriefed
PR n (%) PNR n (%) SR n (%) SNR n (%) TOTAL n (%)
Yes 6 (86%) 9 (82%) 16 (89%) 4 (67%) 35 (83%)
No - 2 (18%) 2 (11%) 1 (17%) 5 (12%)
Inappropriate 1 (14%) - - 1 (17%) 2 (5%)
PR: Placebo Responder; PNR: Placebo Non Responder; SR: Steroid Responder: SNR: Steroid Non Responder
BMC Health Services Research 2005, 5:30 http://www.biomedcentral.com/1472-6963/5/30
Page 7 of 8
(page number not for citation purposes)
ence significant improvements, most hoped they would
achieve some benefit, and the rest worried about possible
drug side-effects rather than anticipating improvement.
The authors also determined that expectations changed as
a result of self-monitoring, a finding that is in line with
Lundh's placebo effect theory [21]. Lundh suggested that
when individuals believe that a treatment will cure them
they will selectively attend to signs of improvement, and
attribute any improvements to the treatment.
The therapeutic role of hope has not been subject of scien-
tific scrutiny, whereas the effects of expectancies have
been much more under investigation, especially in the
placebo effect literature [17,18,22]. It is useful to be aware
of the difference between outcome expectancies, which
are used to refer to consequences that follow actions and
self-efficacy expectancies, or beliefs that one can success-
fully perform the actions required to achieve valued out-
comes [23,24]. A third related construct is that of
optimism, which has been defined as a generalized
expectancy that one will experience good outcomes in life.
While these constructs overlap in that they emphasize a
belief that a desired outcome will occur in the future, they
have been found to be separate. This distinction has been
shown to be both general and robust across contexts,
although "All are related by the central core of expectancies"
(p.18) [19].
These findings point to the broader, multi-dimensional
and dynamic nature of expectations, something which
often fails to be considered in clinical research. In a sys-
tematic review of placebo controlled RCT's examining the
therapeutic effects of treatment expectations [25], we
found that expectations were measured using single item
scales administered at one point in time, thus failing to
capture the complex nature of expectations.
In our survey, when asked about what treatment they
thought they had been randomized to more than half of
the participants (55%, 22 of 42) hesitated to answer, per-
haps afraid to appear foolish due to the negative connota-
tions associated with placebos. Only 37% of the
participants who volunteered to take a guess were able to
correctly identify their treatment allocation, suggesting
that the internal validity of the trial findings were unaf-
fected by a breech in the trial blinding.
Most wanted to be informed about their treatment alloca-
tion and about study results and five individuals refused
to be informed. Reactions to treatment debriefing varied
between surprise, embarrassment, excitement, and attri-
bution to another treatment, typically physiotherapy, to
explain their recovery or improvement. Participants were
generally interested to hear about the study findings, and
three specifically asked to receive any published material
from the study.
We found that participants varied in their understanding
of the study and the treatments being investigated. Some
were very clear about what was being investigated and the
principles of randomization, while some did not realize
they had been recruited into a study.
These findings are in line with a review which found that
trial participants often have difficulty understanding the
concept and purpose of a trial, randomization and dou-
ble-blind procedure [26].
Limitations of the study
Our study is limited by its retrospective nature and the
time that elapsed since the original trial was conducted.
The time lapse was at least a year, depending on the stage
in which participants may have dropped out during the
trial. The delay largely resulted from difficulties in obtain-
ing ethical approval, which took nine months. The time
lapse and the elderly age of these patients may have been
affected patients' recall. Although many trial participants
could not remember the names of the treatments being
investigated, most were able to distinguish between a
pharmacologically active and a non-specific treatment
which they described in their own words as placebo (e.g.
'the one with nothing in it') or the wrong treatment.
The trial is the largest RCT examining the effectiveness of
corticosteroid for heel pain to date. Despite this, the trial
population we were able to follow up was relatively small.
Furthermore, 43% of the participants interviewed
reported that their heel pain was recurrent and for almost
20% it was continuous. The cyclical nature of heel pain
further limits our ability to extrapolate on the relationship
between cognitions and outcomes.
Reactions to debriefing were recorded immediately after
the information was communicated. While this method
identified immediate response to debriefing, research
would benefit from monitoring more long-term effects
and examining debriefing at different time points.
Recommendations
Further research is required to better understand beliefs
around placebo effects, to develop sensitive ways to
inform placebo responders about their treatment alloca-
tion and to evaluate the effects of debriefing. This research
should combine qualitative research alongside a prospec-
tive longitudinal or randomized trial design, using objec-
tive outcomes and large clinical samples. Research in this
area would increase participant involvement, improve
trial methodology and would further our understanding
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around the therapeutic role of thoughts, feelings and
patient-practitioner interactions in RCT's [27].
We recommend that at the informed consent stage inves-
tigators ask eligible trial participants whether they would
like to be informed about trial results and treatment allo-
cation. It is important to try and avoid creating feelings of
embarrassment, mistrust, or disillusionment and to pre-
vent damaging a healing response. For this reason the dis-
tinction between 'placebo' and 'placebo effect' should to
be made at informed consent, so that participants being
enrolled in placebo-controlled trials do not focus on the
possibility of receiving a 'dummy' or 'sham' pill, but are
informed about the effect that derives from feelings and
beliefs, the characteristics of the setting, and the effects of
health care interactions [28]. Highlighting this distinction
at the informed consent stage should help with debriefing
at trial closure.
Conclusion
Our findings emphasize the importance of involving trial
participants at study closure, by sharing study results and
individual treatment allocation, while respecting individ-
uals who do not wish to be debriefed. We recommend
that this information is communicated in a sensitive man-
ner, perhaps discussing placebo effects within a broader
framework by considering the effects of spontaneous
recovery, treatment beliefs and health care interactions.
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